AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30105416 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and severe hypoxemia
Number of subjects: 1604
Study 30105602 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 2487
Study 30105602 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness
Number of subjects: 2487
Study 30105602 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 2487
Study 30105602 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative depression
Number of subjects: 2487
Study 30105657 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 2555
Study 30105657 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (treatment for at least 1 week)
Number of subjects: 2555
Study 30105657 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (treatment for less than 1 week)
Number of subjects: 2555
Study 30105657 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (daily dose 50-100 mg)
Number of subjects: 2555
Study 30105657 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (other daily doses)
Number of subjects: 2555
Study 30105657 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (Candida-infected patients)
Number of subjects: 2555
Study 30105657 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (Aspergillus-infected patients)
Number of subjects: 2555
Study 30105665 — intervention group
Group type: EXPERIMENTAL
Intervention: Current pain intensity
Number of subjects: 606
Study 30105665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbances
Number of subjects: 606
Study 30105665 — intervention group
Group type: EXPERIMENTAL
Intervention: Drowsiness
Number of subjects: 606
Study 30105665 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 606
Study 30105665 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakthrough pain
Number of subjects: 606
Study 30105951 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib, 100 mg daily
Number of subjects: 43
Study 30106639 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarker signature derived from a case-control study using an antibody microarray platform.
Number of subjects: 888
Study 30106639 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarker signature validated in an independent case-control study in the United States.
Number of subjects: 888
Study 30107363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S/Dilasoft use of <12 h (n=188)
Number of subjects: 444
Study 30107363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S/Dilasoft use of >12 h (n=256)
Number of subjects: 444
Study 30107363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S/Dilasoft
Number of subjects: 444
Study 30107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir-elbasvir for 12 weeks
Number of subjects: 122
Study 30107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir-elbasvir for 16 weeks with ribavirin
Number of subjects: 122
Study 30107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk counseling program
Number of subjects: 122
Study 30107485 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 122
Study 30107494 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA-based screening
Number of subjects: 3722
Study 30107798 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes mellitus, overweight
Number of subjects: 384
Study 30107798 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes mellitus, obese
Number of subjects: 384
Study 30107798 — intervention group
Group type: COMPARATOR
Intervention: Controls, overweight
Number of subjects: 384
Study 30107798 — intervention group
Group type: COMPARATOR
Intervention: Controls, obese
Number of subjects: 384
Study 30107798 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain from baseline to follow-up
Number of subjects: 384
Study 30107798 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss from baseline to follow-up
Number of subjects: 384
Study 30107811 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells (BM MNCs)
Number of subjects: 30
Study 30107868 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-INH) 40 IU/kg twice weekly
Number of subjects: 0
Study 30107868 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-INH) 60 IU/kg twice weekly
Number of subjects: 0
Study 30107868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30107868 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-INH (SC)
Number of subjects: 0
Study 30108004 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam radiation therapy (PRT)
Number of subjects: 155
Study 30108004 — intervention group
Group type: COMPARATOR
Intervention: Craniospinal irradiation (CSI)
Number of subjects: 155
Study 30108004 — intervention group
Group type: COMPARATOR
Intervention: Focal PRT
Number of subjects: 155
Study 30108004 — intervention group
Group type: COMPARATOR
Intervention: Older patients
Number of subjects: 155
Study 30108004 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive skills
Number of subjects: 155
Study 30108375 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Kscore test
Number of subjects: 137
Study 30108511 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming in a moving virtual world
Number of subjects: 0
Study 30109471 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome Measures (PROMIS)
Number of subjects: 23
Study 30109728 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a facility pain management policy facilitated by a facility pain champion and training of all care workers in pain assessment and management
Number of subjects: 6
Study 30109728 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups and interviews to explore feasibility and acceptability of the intervention and implementation strategies
Number of subjects: 6
Study 30109845 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882 mg intramuscular every 4 weeks
Number of subjects: 478
Study 30109845 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg intramuscular every 4 weeks
Number of subjects: 478
Study 30109845 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with aripiprazole lauroxil
Number of subjects: 478
Study 30109845 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial injections of aripiprazole lauroxil
Number of subjects: 478
Study 30110589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibalizumab (2000 mg loading dose, then 800 mg every 14 days)
Number of subjects: 40
Study 30111186 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine exposure during first trimester
Number of subjects: 357
Study 30111186 — intervention group
Group type: COMPARATOR
Intervention: No second-generation antipsychotic exposure
Number of subjects: 357
Study 30111326 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Control Test (ACT)
Number of subjects: 0
Study 30111365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (5000-7000 counts per minute)
Number of subjects: 841
Study 30111365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity
Number of subjects: 841
Study 30111365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time and light physical activity
Number of subjects: 841
Study 30111528 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization followed by sorafenib
Number of subjects: 520
Study 30111528 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 520
Study 30111609 — intervention group
Group type: EXPERIMENTAL
Intervention: obinutuzumab, ibrutinib, and venetoclax (fixed-duration regimen, 14 cycles of 28 days each)
Number of subjects: 12
Study 30111609 — intervention group
Group type: EXPERIMENTAL
Intervention: obinutuzumab, ibrutinib, and venetoclax (fixed-duration regimen)
Number of subjects: 12
Study 30112005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30g/day for 12 weeks
Number of subjects: 40
Study 30113201 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscientiousness
Number of subjects: 136
Study 30113201 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning strategies
Number of subjects: 136
Study 30113201 — intervention group
Group type: COMPARATOR
Intervention: Support intensity
Number of subjects: 136
Study 30113351 — intervention group
Group type: EXPERIMENTAL
Intervention: Epileptiform discharges during anaesthesia induction
Number of subjects: 62
Study 30113351 — intervention group
Group type: COMPARATOR
Intervention: No epileptiform discharges during anaesthesia induction
Number of subjects: 62
Study 30113351 — intervention group
Group type: EXPERIMENTAL
Intervention: Interictal spike events (rhythmic polyspikes; periodic epileptiform discharges; delta with spikes)
Number of subjects: 62
Study 30113648 — intervention group
Group type: EXPERIMENTAL
Intervention: Anandamide (AEA)
Number of subjects: 53
Study 30113648 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-arachidonoylglycerol (2-AG)
Number of subjects: 53
Study 30113648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (OEA)
Number of subjects: 53
Study 30113648 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 53
Study 30113648 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific sphingomyelins (SM18:1/23:0, SM18:1/23:1, SM18:1/26:1)
Number of subjects: 53
Study 30113648 — intervention group
Group type: COMPARATOR
Intervention: Sphingomyelins
Number of subjects: 53
Study 30113663 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle biopsies from women with PCOS
Number of subjects: 31
Study 30113663 — intervention group
Group type: COMPARATOR
Intervention: Skeletal muscle biopsies from controls
Number of subjects: 31
Study 30113663 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional follow-up studies on KLF10
Number of subjects: 31
Study 30113681 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR prescribing data linked to claims-based dispensing data
Number of subjects: 0
Study 30113685 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Perioperative Pain Protocol (MP3)
Number of subjects: 252
Study 30113685 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-intervention)
Number of subjects: 252
Study 30113844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual JAK1/TYK2 inhibitor (PF-06700841)
Number of subjects: 0
Study 30113844 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal antibodies (mAbs) or JAK1 inhibitors
Number of subjects: 0
Study 30114960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar CPB prime
Number of subjects: 30
Study 30115015 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest education level (lower than high school)
Number of subjects: 1361
Study 30115015 — intervention group
Group type: EXPERIMENTAL
Intervention: Completed high school education
Number of subjects: 1361
Study 30115015 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly income level < $1500
Number of subjects: 1361
Study 30115015 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly income level $1500-4500
Number of subjects: 1361
Study 30115015 — intervention group
Group type: COMPARATOR
Intervention: Highest education level (reference)
Number of subjects: 1361
Study 30115015 — intervention group
Group type: COMPARATOR
Intervention: Monthly income level > $4500 (reference)
Number of subjects: 1361
Study 30115127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 2377
Study 30115226 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients with emotional triggers (30% of TTS patients)
Number of subjects: 1613
Study 30115226 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients with physical triggers (39% of TTS patients)
Number of subjects: 1613
Study 30115226 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS) patients with no identifiable trigger (31% of TTS patients)
Number of subjects: 1613
Study 30115226 — intervention group
Group type: COMPARATOR
Intervention: Acute coronary syndrome (ACS) patients
Number of subjects: 1613
Study 30115251 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid corrected flow time (FTc)
Number of subjects: 53
Study 30115251 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirophasic variation in carotid artery blood flow peak velocity (ΔVpeak)
Number of subjects: 53
Study 30115541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine plus low-dose cytarabine alternating with decitabine for up to 18 cycles (induction therapy: cladribine 5 mg/m²).
Number of subjects: 118
Study 30115541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine plus low-dose cytarabine alternating with decitabine.
Number of subjects: 118
Study 30115596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine (70 mg/m²) followed by obinutuzumab and venetoclax
Number of subjects: 66
Study 30115596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine followed by obinutuzumab and venetoclax
Number of subjects: 66
Study 30115688 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative myocardial perfusion severity analysis
Number of subjects: 0
Study 30115734 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib 300 mg plus chemotherapy
Number of subjects: 55
Study 30115734 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib
Number of subjects: 55
Study 30115734 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 55
Study 30116539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 1247
Study 30116539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study 30116592 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AAP)
Number of subjects: 211
Study 30116592 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide (ENZ)
Number of subjects: 211
Study 30117142 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30117149 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m² weekly for 4 cycles
Number of subjects: 63
Study 30117149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine (specific dosage not mentioned)
Number of subjects: 63
Study 30117309 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction-based weight loss smartphone app with coaching
Number of subjects: 18
Study 30117309 — intervention group
Group type: COMPARATOR
Intervention: EMPOWER clinic program (control)
Number of subjects: 18
Study 30117761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT) - 470 kCal
Number of subjects: 62
Study 30117761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-arginine (arginine maximal stimulation test - AST, 5 g)
Number of subjects: 62
Study 30118386 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-RIT
Number of subjects: 1736
Study 30118386 — intervention group
Group type: COMPARATOR
Intervention: MMR II
Number of subjects: 1736
Study 30118397 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiation therapy (RT)
Number of subjects: 222
Study 30118633 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge dose of monovalent HBV vaccine
Number of subjects: 302
Study 30118852 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 315
Study 30118942 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT + GDMT
Number of subjects: 264
Study 30118942 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 264
Study 30119089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm pacing system with spinal cord stimulation
Number of subjects: 3
Study 30119089 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm pacing system
Number of subjects: 3
Study 30119089 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 3
Study 30119715 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 239
Study 30119715 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 239
Study 30119925 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy (received by 402 patients, 48.4%)
Number of subjects: 831
Study 30120161 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib administered daily for 3 weeks of each 4-week cycle until disease progression or other reason.
Number of subjects: 0
Study 30120268 — intervention group
Group type: EXPERIMENTAL
Intervention: Indibulin
Number of subjects: 0
Study 30120268 — intervention group
Group type: EXPERIMENTAL
Intervention: Indibulin + Vinblastine
Number of subjects: 0
Study 30120268 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine and Colchicine
Number of subjects: 0
Study 30120281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 0
Study 30120281 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 30120518 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (Dysport) injection cycles
Number of subjects: 150
Study 30120839 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial electromyography (EMG) during fMRI BOLD sequence
Number of subjects: 16
Study 30120956 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet heparin suction
Number of subjects: 40
Study 30120956 — intervention group
Group type: COMPARATOR
Intervention: Dry heparin suction
Number of subjects: 40
Study 30120956 — intervention group
Group type: COMPARATOR
Intervention: Dry needle biopsy
Number of subjects: 40
Study 30120956 — intervention group
Group type: COMPARATOR
Intervention: Dry techniques
Number of subjects: 40
Study 30120956 — intervention group
Group type: COMPARATOR
Intervention: Dry heparin
Number of subjects: 40
Study 30121090 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-ECMO support
Number of subjects: 48
Study 30121090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate levels
Number of subjects: 48
Study 30121090 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory parameters
Number of subjects: 48
Study 30121138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoid CB
Number of subjects: 0
Study 30121271 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast arterial calcification (BAC) presence
Number of subjects: 2100
Study 30121271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low bone mass (LBM) presence
Number of subjects: 2100
Study 30121271 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of BAC presence to 10-year ASCVD risk
Number of subjects: 2100
Study 30121419 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban treatment
Number of subjects: 3797
Study 30121602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib monotherapy
Number of subjects: 84
Study 30121602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib in combination with trametinib
Number of subjects: 84
Study 30121602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib monotherapy or combination therapy
Number of subjects: 84
Study 30121613 — intervention group
Group type: EXPERIMENTAL
Intervention: Small volume plasma exchange (SVPE)
Number of subjects: 20
Study 30121827 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg with loading dose
Number of subjects: 350
Study 30121827 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg without loading dose
Number of subjects: 350
Study 30121827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 30121892 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 53
Study 30121938 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (RT) at a maximum tolerated dose (MTD) of 20 Gy delivered in 2 days, twice daily.
Number of subjects: 45
Study 30122202 — intervention group
Group type: EXPERIMENTAL
Intervention: MPN-SAF TSS (Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score); range 0-100
Number of subjects: 2309
Study 30122202 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer-Core Quality of Life Questionnaire, version 3.0); range 0-100
Number of subjects: 2309
Study 30122202 — intervention group
Group type: EXPERIMENTAL
Intervention: WPAI-SHP (Work Productivity and Activity Impairment Questionnaire-Specific Health Problem); range 0%-100
Number of subjects: 2309
Study 30122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 2.5 mg BID
Number of subjects: 0
Study 30122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5.0 mg BID
Number of subjects: 0
Study 30122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 10.0 mg BID
Number of subjects: 0
Study 30122926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30123324 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based physical activity data collection
Number of subjects: 0
Study 30123511 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiogram-guided resuscitation (ECHO)
Number of subjects: 30
Study 30123511 — intervention group
Group type: COMPARATOR
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 30
Study 30123522 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteboard animation video for parents about AGE
Number of subjects: 0
Study 30123522 — intervention group
Group type: COMPARATOR
Intervention: Sham control video
Number of subjects: 0
Study 30123525 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of participation in a rehabilitation program led by a Case Manager
Number of subjects: 130
Study 30123525 — intervention group
Group type: COMPARATOR
Intervention: Usual community aged care
Number of subjects: 130
Study 30123524 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Mental Imagery Training (PMIT) + Treatment as Usual (TAU)
Number of subjects: 90
Study 30123524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CCT) + Treatment as Usual (TAU)
Number of subjects: 90
Study 30123524 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 90